Introduction
============

Topical ophthalmic anesthesia is a part and parcel of ophthalmic examinations and procedures these days. It is widely used because of its rapid onset, easy application, and the low risk of side effects. There are many different types of topical anesthetic agents. Tetracaine is one of the most common topical anesthetics used in general practice due to its efficacy and wide availability.

While instillation of tetracaine is easy and lasts long enough for most ophthalmic examinations and procedures, it can often cause burning sensation and ocular pain.[@b1-opth-12-2377]--[@b4-opth-12-2377] These adverse effects can be very unpleasant to the patients and they are the main limitations of tetracaine use in clinical practice. Various studies have tried to look into ways of attenuating these adverse effects.[@b1-opth-12-2377]--[@b3-opth-12-2377],[@b5-opth-12-2377]--[@b10-opth-12-2377] Adjusting the temperature of the solution may be a viable option for this.

There have been few studies regarding the effect of temperature of tetracaine solution on burning sensation.[@b1-opth-12-2377],[@b11-opth-12-2377],[@b12-opth-12-2377] The results of these studies suggested that lowering the temperature of tetracaine eye drop may alleviate ocular pain on instillation.[@b11-opth-12-2377],[@b12-opth-12-2377] However, the sample size of these studies was relatively small and was not statistically calculated. In addition, nearly all these studies were performed in healthy volunteers[@b12-opth-12-2377],[@b13-opth-12-2377] and only one study was conducted in patients undergoing phacoemulsification.[@b11-opth-12-2377] As such, the outcome of these findings may not be generalizable to the patients undergoing ophthalmic examination in ophthalmology clinic.

In view of this, we conducted a prospective, double-blinded, randomized controlled trial comparing the effect of cold vs room temperature topical tetracaine on the severity of burning sensation in all comers of the ophthalmic outpatient clinic.

Patients and methods
====================

This was a prospective, double-blinded, randomized controlled clinical trial conducted during January 2016--February 2017.

Consecutive patients attending the ophthalmic outpatient department at Phramongkutklao Hospital, who met the following criteria, were included in the study: age 20 years and above, imperative dilated fundus examination in both eyes and well communicative. The patients who had history of keratopathy or neuropathy (evaluated by using the Cochet--Bonnet esthesiometer \[C-BA\] \<2 cm) were excluded. Written informed consent was obtained in all patients. The study was approved by the institutional review board of the Royal Thai Army Medical Department.

We prepared two groups of 0.5% tetracaine hydrochloride ophthalmic solution (Alcon Laboratories, Inc., Fort Worth, TX, USA). The first group was kept in the refrigerator (4°C) at least 24 hours before using, whereas the other group was stored at room temperature (mean 22.5°C, range 22°C--23°C).

Demographic data, ocular history (ocular disease, history of previous ophthalmic surgery, history of contact lenses wear and frequency of the previous tetracaine eye drop instillation) and findings of ocular examination (visual acuity, corneal sensation using the C-BA, Schirmer I test) were recorded.

The subjects were randomized to receive cold or room temperature tetracaine in one eye, followed by the other solution in the other eye using block of 4 randomization. They were not informed whether the solution was cold or at room-temperature. We also wanted to study the impact of instillation sequence on the severity of side effects. Therefore, the sequence of instillation was also randomized. Half of the subjects were randomized to receive instillation of cold tetracaine first followed by the room temperature solution in the other eye, whereas the other half received instillation of room temperature tetracaine first followed by cold solution. Each adverse symptom was thoroughly evaluated using a constructed questionnaire. The severity of each symptom was assessed using a 100 mm visual analog scale (VAS) by one researcher who was blinded to the treatment allocation.

Sample size
-----------

Assuming an SD of the VAS of 24.29 and setting a % error of 5, the minimum sample size was set at 342 with a 0.90 power to detect a difference of six between the groups.

Statistical analyses
--------------------

Statistical analyses were performed using SPSS software version 23.0 (IBM Corporation, Armonk, NY, USA). Continuous variables were analyzed using the unpaired Student's *t*-test or paired *t*-test as appropriate. The chi-squared test or Fisher's exact test was used to evaluate categorical data as appropriate. *P*-values \<0.05 were considered statistically significant.

Results
=======

A total of 424 patients were enrolled in the study. Mean±SD age was 59.84±15.80 years. The numbers of female and male were almost equal. Almost 70% had no history of dry eye disease. The demographic data are shown in [Table 1](#t1-opth-12-2377){ref-type="table"}. We performed the analysis on the sequence of instillation and we did not find the order effect.

Patients who received cold tetracaine reported significantly less burning sensation than with room temperature tetracaine (20.50±18.8 and 22.70±20 mm, respectively; *P*-value 0.025), as shown in [Figure 1](#f1-opth-12-2377){ref-type="fig"}. However, other symptoms including eye pain, eye irritation, tearing and blurred vision were not statistically different. No complications were observed throughout the study.

We performed further analysis to identify the subgroups of patients who reported higher VAS score of burning sensation and the subgroups that showed more benefit from using cold tetracaine ([Tables 2](#t2-opth-12-2377){ref-type="table"} and [3](#t3-opth-12-2377){ref-type="table"}).

Patients who had no previous history of ocular surgery had more VAS burning sensation score (22.7±20.0 vs 19.1±18.0 mm; *P*=0.008). Patients who had preserved corneal sensation (C-BA \>3 cm) also reported more severe burning sensation compared to patients who had impaired corneal sensation (25.8±20.2 vs 21.4±19.1 mm; *P*=0.011). Patients who used tetracaine for the first-time in the previous year (first-time users) reported more burning sensation compared to patients who had experience of using tetracaine at least once in the previous year (24.8±11.3 vs 19.4±18.1 mm; *P*\<0.001). There was a trend for more severe VAS score in female and younger patients, although the difference did not reach statistical significance as shown in [Table 2](#t2-opth-12-2377){ref-type="table"}.

Female and younger patients reported more beneficial effect from cold tetracaine (20.8±19.6 vs 24.5±20.5 mm, *P*=0.007 and 23.5±19.3 vs 35.7±24.3 mm, *P*\<0.001, respectively). Patients who had no history of previous ocular surgery, the subgroup that was expected to have intact corneal sensation, had significantly less burning sensation score with cold tetracaine. Subjects who used tetracaine for the first-time in the previous year (first-time user) also had more benefit from cold tetracaine (21.9±20.7 vs 27.9±21.7; *P*=0.001). Participants who had preserved corneal sensation (C-BA.3 cm) experienced more beneficial effect from cold tetracaine (23.8±19.1 vs 28.1±21.4; *P*=0.009) as shown in [Table 3](#t3-opth-12-2377){ref-type="table"}.

Discussion
==========

Tetracaine is the most commonly used topical eye anesthesia due to its efficacy and safety.[@b2-opth-12-2377],[@b3-opth-12-2377] However, it has some adverse effects such as burning sensation upon instillation and ocular irritation.[@b4-opth-12-2377] Due to this adverse effect, it may reduce patient cooperation after tetracaine is instilled. There have been attempts to find ways to decrease these limitations.

Li et al[@b12-opth-12-2377] conducted a crossover study in a 22 healthy subjects and compared ocular pain upon instillation between cold (4°C) and room temperature (19°C--21°C) tetracaine. The volunteers received one temperature in one eye and after at least 24 hours received alternate temperature in the same eye. VAS score was recorded right after tetracaine was instilled. They found that ocular pain was lessened when tetracaine was stored in cold temperature compared to room temperature. The limitation of this study is that VAS score was recorded on a different day, therefore making it difficult to recall. Furthermore, the number of subjects in the studied population was small.

In their study, Soltani et al[@b11-opth-12-2377] recruited 60 patients, aged 50--70 years, undergoing phacoemulsification. This study compared ocular pain upon instillation of cold and room temperature tetracaine. Each subject was randomized to receive only cold or room temperature tetracaine. It was found that cooling tetracaine reduced the pain on instillation compared to room temperature solution. This study recruited the subjects who were undergoing phacoemulsification. This is more generalizable than the study of Li et al,[@b12-opth-12-2377] who recruited healthy persons as their study subjects. However, as the effects of room temperature and cold tetracaine were assessed in two different populations of patients, there might be differences in baseline characteristics of both the groups, which lead to the possibility of selection bias and confounders, hence limiting the internal validity of the study.

Callear[@b1-opth-12-2377] studied 60 subjects. The author randomized patients into three groups, with 20 patients in each, to receive amethocaine or oxybuprocaine or lignocaine eye drops. Each patient received warm temperature (42°C) topical anesthetic in one eye and the same solution at room temperature (22°C--25°C) in the other eye. The result showed that there was no significant difference in the discomfort caused by different temperatures (warm vs room temperature) in any of the three anesthetic drugs.

The study of Mansour et al[@b8-opth-12-2377] compared the effects of warm (20°C) and cold temperature (4°C) on ocular discomfort of the dilating drops (tropicamide and phenylephrine) in 40 patients. Each patient received cold solutions in one eye and warm solutions in the other eye. The result showed that there was no difference in ocular discomfort between cold and warm dilating eye drops.

Based on the previous studies, the effect of temperature on burning sensation upon instillation of topical eye drops is still controversial. This led us to conduct the double-blinded, randomized controlled trial with a large sample size in order to answer this important research question.

The result of our study showed that cold temperature tetracaine caused less burning sensation than room temperature tetracaine upon instillation. This conformed to the findings of the studies of Li et al[@b12-opth-12-2377] and Soltani et al.[@b11-opth-12-2377]

The mechanism of how cooling tetracaine reduces the burning sensation could be explained by many theories. Cold temperature could reduce the nerve conduction velocity[@b14-opth-12-2377] and lead to pain reduction. Cold pack or icepack is used to reduce pain in the musculoskeletal system,[@b15-opth-12-2377],[@b16-opth-12-2377] and its onset of effect seems to be very rapid. Therefore, it is very likely that one of the main mechanisms by which cold temperature tetracaine alleviates burning sensation could be explained by the direct effect of temperature on nerve conduction. Through this mechanism, cold ophthalmic solutions, including tetracaine and artificial tears, have been found to be effective in pain reduction.[@b11-opth-12-2377],[@b17-opth-12-2377] Fujishima et al[@b17-opth-12-2377] found that cooled artificial tears decreased corneal sensation and gave comfort to the patient. Vasoconstriction caused by cold temperature is another mechanism that plays an important role in pain reduction. Previous studies have shown that the cold ophthalmic solution induces vasoconstriction[@b15-opth-12-2377],[@b16-opth-12-2377],[@b18-opth-12-2377] and could reduce the inflammatory cells and mediators. One study showed that cold pack applied after cataract surgery reduced inflammation. In the study, the authors evaluated inflammation using laser flare-cell meter. They found that there was a significant cell count reduction in inflammation on days 1, 3, 7 and 14 and a significant reduction in flare counts on days 1, 14 and 28 after surgery in the cooled eye.[@b19-opth-12-2377]

In our study, for room temperature tetracaine, mean VAS was 22.70±20 mm, which was much less than that reported in other studies (mean VAS scores were 35.5±17.5[@b11-opth-12-2377] and 49±22 mm^12^). The reduction of 2.7 from 22.7 iŝ10%, which was in accordance with the other study,[@b12-opth-12-2377] and we would expect the reduction to be greater in patients with inflamed eyes or in those who are more sensitive to tetracaine solution. In addition, we assessed patients' preference between cold and room temperature tetracaine and found that most of the patients preferred cold to room temperature tetracaine and some patients found no difference between the two solutions (45.5% vs 31.8% vs 22.7%, respectively). Thus, we believe that the difference might have clinical significance, and cold solution could be beneficial in many patients who suffer from this common side effect of tetracaine. Moreover, different cultural backgrounds of different study populations may also play some role. Thai people are usually much more considerate. It is quite unusual for Thai patients to complain or express their feeling to their physicians. They tend to express less pain or discomfort than what they actually feel when asked by medical personnel. Nevertheless, the benefit of cold tetracaine was observed even in patients with low VAS score as in our study. We expect that the benefit of using cold tetracaine might even be more substantial if used in patients with higher VAS score.

In the subgroup analysis, we found that the patients who had no previous ocular surgery, the patients who had preserved corneal sensation (C-BA \>3 cm) and the patients who used tetracaine for the first time in the previous year, had more VAS burning sensation score (sensitive subgroups). These sensitive subgroups of patients, who experienced more pain with tetracaine, were found to have greater benefit from using cold solution. This suggests that cold tetracaine is especially useful in those who are expected to experience more pain.

The strengths of our study are as follows. First, it is the largest double-blinded, randomized controlled trial to date. Second, the sample size was precalculated and was large enough for subgroup analysis. Third, we performed C-BA to evaluate corneal sensation, whereas in most of the other studies, the subjects were excluded by using the history of corneal neuropathy. Fourth, the sequence of instillation of tetracaine was also randomized. We found that the sequence had no impact on the patients' perspective of pain. Fifth, this is the first study that performed a subgroup analysis and provided extended knowledge to be applied to clinical practice.

The limitation of our study is that, we neither assessed the duration of discomfort nor the efficacy of anesthesia.

The results of this study lead to an important clinical implication. We recommend storing tetracaine in a refrigerator and using cold tetracaine to reduce burning sensation upon instillation in routine clinical practice, especially to sensitive groups of patients.

The effect of cold temperature that was found in this study should be further studied with broader groups of patients, such as patients who have inflamed eye, patients with corneal ulcer, patients with neuropathic pain or patients who have painful eye disease.

Conclusion
==========

Cold ophthalmic tetracaine causes less burning sensation than room temperature solution. Its benefit is more in the subgroup of patients who experience greater burning sensation.
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![Comparison of mean VAS scores of the symptoms between instillation of cold tetracaine vs room temperature tetracaine.\
**Note:** The VAS burning sensation score of cold tetracaine was significantly lower than that of room temperature solution (*P*-value 0.025).\
**Abbreviation:** VAS, visual analog scale.](opth-12-2377Fig1){#f1-opth-12-2377}

###### 

Demographic characteristics of the study population

                              Total number of subjects (N=424)
  --------------------------- ----------------------------------
  Age, mean±SD                
  Gender, n (%)               
   Female                     219 (51.7)
   Male                       205 (48.3)
  History of surgery, n (%)   
   No                         280 (66)
   Yes                        144 (34)
  Hypertension, n (%)         222 (52.4)
  Diabetic mellitus, n (%)    199 (46.9)
  Dry eye disease, n (%)      
   No                         287 (67.7)
   Yes                        137 (32.3)
  Glaucoma, n (%)             
   No                         375 (88.4)
   Yes                        49 (11.6)

###### 

Subgroups of patients and VAS score of burning sensation at room temperature (independent sample *t*-test)

                                         n     VAS score of burning sensation (mean±SD)   *P*-value
  -------------------------------------- ----- ------------------------------------------ ------------------------------------------------------
  Age, years                                                                              
   ≤40                                   49    23.4±19.3                                  0.241
   \>40                                  375   20.1±18.7                                  
  Gender                                                                                  
   Male                                  205   20.5±18.7                                  0.111
   Female                                219   22.6±20.1                                  
  Corneal sensation                                                                       
   C-BA \>3 cm (normal)                  102   25.8±20.2                                  0.011[\*](#tfn1-opth-12-2377){ref-type="table-fn"}
   C-BA ≥3 cm (impaired)                 183   21.4±19.1                                  
  Tetracaine used in the previous year                                                    
   Yes                                   242   19.4±18.1                                  \<0.001[\*](#tfn1-opth-12-2377){ref-type="table-fn"}
   No                                    137   24.8±11.3                                  
  History of ocular surgery                                                               
   Yes                                   143   19.1±18.0                                  0.008[\*](#tfn1-opth-12-2377){ref-type="table-fn"}
   No                                    277   22.7±20.0                                  
  Dry eye disease                                                                         
   Yes                                   137   21.0±18.5                                  0.124
   No                                    287   22.6±19.7                                  
  Glaucoma                                                                                
   Yes                                   49    21.0±19.8                                  0.751
   No                                    375   21.6±19.4                                  
  Diabetic retinopathy                                                                    
   Yes                                   82    17.3±17.1                                  0.163
   No                                    342   20.9±19.2                                  

**Note:**

*P*\<0.05.

**Abbreviations:** C-BA, Cochet--Bonnet esthesiometer; VAS, visual analog scale.

###### 

Comparison of burning sensation assessed by VAS score between cold tetracaine and room temperature tetracaine in different subgroups (paired *t*-test, α=0.05)

  Demographic data                       Burning sensation VAS score (mm)   *P*-value                
  -------------------------------------- ---------------------------------- ------------ ----------- ---------
  Age, years                                                                                         
   ≤40                                   49                                 23.5±19.3    35.7±24.3   \<0.001
   \>40                                  375                                20.1±18.71   20.9±18.7   0.415
  Gender                                                                                             
   Male                                  205                                20.2±18.0    20.8±19.4   0.695
   Female                                219                                20.8±19.6    24.5±20.5   0.007
  Corneal sensation, cm                                                                              
   \>3                                   102                                23.8±19.1    28.1±21.4   0.009
   ≤3                                    183                                20.7±18.5    21.8±19.2   0.57
  Tetracaine used in the previous year                                                               
   First-time user                       137                                21.9±20.7    27.9±21.7   0.001
   More than one time user               242                                19.7±18.3    19.2±17.9   0.676
  History of ocular surgery                                                                          
   No                                    277                                21.1±19.4    24.4±20.6   0.006
   Yes                                   143                                19.1±17.5    19.0±18.5   0.949
  Dry eye disease                        137                                18.5±19.5    22.7±20.9   0.08
  Diabetic retinopathy                                                                               
   No                                    342                                21.3±19.1    23.9±20.6   0.076
   Yes                                   82                                 17.2±17.1    17.1±17.5   0.973

**Abbreviation:** VAS, visual analog scale.
